[go: up one dir, main page]

NO20013155L - Fremgangsmate ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi - Google Patents

Fremgangsmate ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi

Info

Publication number
NO20013155L
NO20013155L NO20013155A NO20013155A NO20013155L NO 20013155 L NO20013155 L NO 20013155L NO 20013155 A NO20013155 A NO 20013155A NO 20013155 A NO20013155 A NO 20013155A NO 20013155 L NO20013155 L NO 20013155L
Authority
NO
Norway
Prior art keywords
cyclooxygenase
neoplasia
inhibitor
treatment
combination therapy
Prior art date
Application number
NO20013155A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013155D0 (no
Inventor
John P Mckearn
Gary Gordon
James J Cunningham
Stephen T Gately
Alane T Koki
Jaime L Masferrer
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO20013155D0 publication Critical patent/NO20013155D0/no
Publication of NO20013155L publication Critical patent/NO20013155L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
NO20013155A 1998-12-23 2001-06-22 Fremgangsmate ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi NO20013155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11378698P 1998-12-23 1998-12-23
PCT/US1999/030693 WO2000038730A2 (fr) 1998-12-23 1999-12-22 Techniques permettant d'utiliser un inhibiteur de cyclooxygenase-2 et un ou plusieurs agents antineoplasiques comme therapie combinee pour traiter les maladies neoplasiques

Publications (2)

Publication Number Publication Date
NO20013155D0 NO20013155D0 (no) 2001-06-22
NO20013155L true NO20013155L (no) 2001-08-22

Family

ID=22351515

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20013155A NO20013155L (no) 1998-12-23 2001-06-22 Fremgangsmate ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi
NO20013156A NO20013156L (no) 1998-12-23 2001-06-22 Fremgangsmate ved anvendelse av en cyklooksygenase-2- inhibitor, samt en matrise-metalloproteinase-inhibitor som enkombinasjonsbehandling ved behandling av neoplasier

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20013156A NO20013156L (no) 1998-12-23 2001-06-22 Fremgangsmate ved anvendelse av en cyklooksygenase-2- inhibitor, samt en matrise-metalloproteinase-inhibitor som enkombinasjonsbehandling ved behandling av neoplasier

Country Status (20)

Country Link
US (1) US6689787B1 (fr)
EP (8) EP1140179A2 (fr)
JP (8) JP2002533422A (fr)
KR (2) KR20010110310A (fr)
CN (3) CN1371286A (fr)
AT (1) ATE322290T1 (fr)
AU (8) AU783992B2 (fr)
BR (2) BR9916518A (fr)
CA (8) CA2356462A1 (fr)
CZ (2) CZ20012320A3 (fr)
DE (1) DE69930764D1 (fr)
EA (2) EA006294B1 (fr)
HU (2) HUP0104747A3 (fr)
IL (2) IL143870A0 (fr)
MX (1) MXPA01006499A (fr)
NO (2) NO20013155L (fr)
PL (2) PL350291A1 (fr)
TR (1) TR200102499T2 (fr)
WO (8) WO2000038719A1 (fr)
ZA (2) ZA200105055B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US20030225150A1 (en) * 1997-04-21 2003-12-04 Pharmacia Corporation Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US7029652B2 (en) * 1998-09-16 2006-04-18 The Regents Of The University Of California Method of treating tumors
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
YU57101A (sh) 1999-02-08 2005-06-10 G.D. Saerle & Co. Sulfamat hidroksamična kiselina inhibitor metaloproteaze
WO2000069819A1 (fr) * 1999-05-12 2000-11-23 G.D. Searle & Co. Composes sulfonyle aryle ou heteroaryle d'acide hydroxamique
AU5140300A (en) 1999-05-17 2000-12-05 Ilex Oncology, Inc. Dfmo and celecoxib in combination for cancer chemoprevention and therapy
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
AU7373600A (en) * 1999-09-15 2001-04-17 American Home Products Corporation Method of potentiating chemotherapy and treating solid tumors
US7465754B1 (en) 1999-09-15 2008-12-16 Wyeth Method of potentiating chemotherapy and treating solid tumors
WO2001035956A1 (fr) * 1999-11-15 2001-05-25 Advanced Research And Technology Institute, Inc. Utilisation des ains dans le traitement du cancer du pancreas
RU2240826C2 (ru) 2000-02-03 2004-11-27 Эйсай Ко., Лтд. Ингибитор экспрессии интегрина
AU2000237154A1 (en) * 2000-02-28 2001-09-12 Zila, Inc. Method for detecting and killing epithelial cancer cells
AU2001250401B2 (en) 2000-03-24 2005-08-11 Novartis Ag Improved treatment of neovascularization
EP1138680A1 (fr) * 2000-03-29 2001-10-04 Pfizer Products Inc. Acides gem-substitués alpha-sulfonylamino hydroxamiques comme inhibiteurs de métalloprotease
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
WO2002019982A2 (fr) * 2000-06-29 2002-03-14 Quick Med Technologies, Inc. Composition et procede cosmetiques
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
AR034142A1 (es) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
CN1729002A (zh) * 2000-09-08 2006-02-01 法玛西雅意大利公司 依西美坦作为化学预防剂
EP1377298B1 (fr) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane pour traiter les troubles hormonodependants
EP1383490B1 (fr) 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combinaison d'un analogue d'epothilone et d'agents chimiotherapeutiques servant au traitement de maladies proliferatives
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
EP2292251A1 (fr) 2001-04-24 2011-03-09 Merck Patent GmbH Polythérapie à base d'agents antiangiogéniques et de facteur de nécrose tumorale TNF-alpha
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
CN100338041C (zh) * 2001-05-03 2007-09-19 霍夫曼-拉罗奇有限公司 明胶酶抑制剂与抗肿瘤剂的组合以及其应用
WO2003000194A2 (fr) 2001-06-21 2003-01-03 Pfizer Inc. Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
WO2003013534A2 (fr) * 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Moyens et procedes de traitement ameliore du cancer sur la base de cyp3a5
WO2003035081A1 (fr) * 2001-10-19 2003-05-01 Novartis Ag Composition pharmaceutique servant a traiter des tumeurs malignes et comprenant une combinaison de biphosphonate, d'inhibiteur de cox-2 et de taxol
MXPA04003878A (es) * 2001-10-25 2004-07-08 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.
RS52500B (sr) * 2001-12-03 2013-04-30 Bayer Healthcare Llc Aril urea jedinjenja u kombinaciji sa drugim citostatičkim ili citotoksičnim agensima za tretiranje humanih kancera
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
WO2003074529A2 (fr) 2002-03-01 2003-09-12 Pfizer Inc. Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
CA2478239A1 (fr) * 2002-03-04 2003-09-18 Medimmune, Inc. Prevention ou traitement de cancer au moyen d'antagonistes de l'integrine alphavbeta3 combines a d'autres agents
JP2005526760A (ja) * 2002-03-08 2005-09-08 ノバルティス アクチエンゲゼルシャフト 癌を処置するための低体温法および／または放射線治療との組合せにおけるマトリックス・メタロプロテイナーゼ阻害剤
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
WO2003091247A2 (fr) 2002-04-25 2003-11-06 Pharmacia Corporation Acides piperidinylsulfonylmethylhydroxamiques et piperazinylsulfonylmethylhydroxamiques et leur utilisation comme inhibiteurs de protease
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
AU2003281169A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
MXPA05000722A (es) * 2002-07-17 2005-04-08 Warner Lambert Co Combinacion de un inhibidor alosterico carboxilico de la metaloproteinasa-13 de la matriz con un inhibidor selectivo de la ciclooxigenasa-2 que no es celecoxib o valdecoxib.
AU2003250483A1 (en) * 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
RS20050430A (sr) 2002-12-19 2007-08-03 Pfizer Inc., Jedinjenja 2-(1h-indazol-6-ilamino)- benzamida kao inhibitori protein kinaza, korisni u tretmanu oftalmoloških bolesti
CA2519310A1 (fr) * 2003-03-18 2004-09-30 Maria Adele Pacciarini Polytherapie comprenant l'administration combinee de nemorubicine et d'un inhibiteur de la cyclo-oxygenase-2
DE10313272A1 (de) * 2003-03-24 2004-10-21 Baxter Healthcare S.A. Verwendung von Miltefosine zur Behandlung von aktinischer oder multiplen aktinischer Keratosen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE602004002832T2 (de) 2003-05-07 2007-06-06 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
CA2536321A1 (fr) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacetamides et leurs derives utiles comme nouveaux agents anti-angiogeniques
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
WO2005043155A1 (fr) 2003-10-21 2005-05-12 Cedars-Sinai Medical Center Systeme et methode pour le traitement du cancer, notamment des cancers du systeme nerveux central
BRPI0418102A (pt) 2003-12-23 2007-04-27 Pfizer derivados de quinolina
EP1765336A4 (fr) 2004-06-25 2010-03-10 Univ Johns Hopkins Inhibiteurs d'angiogenese
PT1786785E (pt) 2004-08-26 2010-05-21 Pfizer Compostos amino-heteroarilo enantiomericamente puros como inibidores da proteína quinase
EP1859797A4 (fr) * 2005-02-28 2011-04-13 Eisai R&D Man Co Ltd Nouvelle utilisation concomitante d'un compose de sulfonamide avec un agent anti-cancer
US7399335B2 (en) * 2005-03-22 2008-07-15 H.C. Starck Inc. Method of preparing primary refractory metal
US20090130098A1 (en) * 2006-01-18 2009-05-21 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
DE102006037158A1 (de) * 2006-08-02 2008-02-14 Bioxsys Gmbh Verfahren zur Feststellung der Sensitivität von Tumoren gegenüber Capecitabin und Testkit
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
AU2008207095B2 (en) 2007-01-18 2013-08-29 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
JP5079023B2 (ja) * 2007-03-23 2012-11-21 エフ．ホフマン−ラ ロシュ アーゲー 肺癌用マーカーとしてのａｐｅｘ
GB2462235B8 (en) * 2007-05-11 2013-03-27 Biotechnology Res Corp Ltd Receptor modulators exhibiting neuroprotective andmemory enhancing activities
US8377922B2 (en) * 2007-11-16 2013-02-19 Ube Industries, Ltd. Benzazepinone compound
KR20100128281A (ko) * 2008-01-23 2010-12-07 릭스하스피탈렛 바이오마커 와이케이엘-40의 수준을 측정함으로써 발견되는 생존 예후에 따른 심혈관계 질환에 걸린 개체들의 분류 방법
EP2245459A1 (fr) 2008-01-23 2010-11-03 Herlev Hospital Ykl-40 en tant que marqueur général pour une maladie non spécifique
CN103588678A (zh) * 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
WO2010028066A2 (fr) 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Épitopes cd133
US8580520B2 (en) 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
ES2618573T3 (es) 2009-05-07 2017-06-21 ImmunoCellular Therapeutics,Ltd Epítopos de CD133
PL2430452T3 (pl) * 2009-05-14 2014-12-31 Arizona Board Of Regents On Behalf Of Univ Of Arizona Diagnoza i leczenie raka w oparciu o genotyp odc1
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
EA201101651A1 (ru) 2009-05-25 2012-08-30 Мерк Патент Гмбх Непрерывное введение интегриновых лигандов для лечения рака
RS59494B1 (sr) 2010-02-12 2019-12-31 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4, 3-cd]indol-6-ona
US8515525B2 (en) * 2011-08-16 2013-08-20 Women's Imaging Solutions Enterprises Llc Skin adhesive agent for mammography procedures
JP6426001B2 (ja) 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
WO2014127296A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Vaccins contre le cancer et méthodes de vaccination
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014150996A1 (fr) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Traitement contre le cancer
LT3929196T (lt) 2013-09-24 2023-09-25 Fujifilm Corporation Farmacinė kompozicija junginio, kurio sudėtyje yra azotas arba jo druska, arba jo metalo kompleksas
WO2015048467A1 (fr) * 2013-09-27 2015-04-02 Cerulean Pharma Inc. Traitement du cancer
EP3094342A4 (fr) 2014-01-15 2017-12-27 Nikolai Khodarev Thérapie anti-tumorale
WO2016097918A1 (fr) 2014-12-18 2016-06-23 Pfizer Inc. Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
MX390899B (es) 2015-10-30 2025-03-21 Cancer Prevention Pharmaceuticals Inc Formulación de combinación de dosis fija, eflornitina y sulindaco.
US9782370B2 (en) * 2015-12-21 2017-10-10 Gongwin Biopharm Holdings Co., Ltd. Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
WO2017117130A1 (fr) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Procédés d'inhibition de libération de virus de l'immunodéficience humaine (vih) à partir de cellules infectées
ES2806276T3 (es) 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
US20170273926A1 (en) * 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
FI3490560T3 (fi) 2016-07-29 2025-02-27 Janssen Pharmaceutica Nv Niraparibi käytettäväksi eturauhassyövän hoitomenetelmässä
WO2018045289A1 (fr) 2016-09-02 2018-03-08 Zon Leonard I Méthodes de traitement du carcinome adénoïde kystique
MX390145B (es) 2016-10-06 2025-03-20 Orbus Therapeutics Inc Formulaciones para la administracion de eflornitina
CN106389429A (zh) * 2016-12-02 2017-02-15 郑州莉迪亚医药科技有限公司 一种治疗老年痴呆症的西药组合物及其应用
US11426385B2 (en) 2017-08-25 2022-08-30 The Regents Of The University Of California Methods of improving cancer chemotherapy
CN111777615B (zh) * 2020-07-20 2022-04-19 济南大学 一种检测环氧合酶2的光动力治疗探针及其制备
CN114767868B (zh) * 2022-03-30 2023-04-18 宁夏医科大学 Cox-2抑制剂与化疗药物在制备抗肿瘤药物中的应用
WO2024184889A1 (fr) * 2023-03-08 2024-09-12 Ariel Scientific Innovations Ltd. Méthodes de traitement

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US5039805A (en) 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (fr) 1989-02-23 2001-11-20 Thomas Weller Derives de glycine
US5686569A (en) 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5061693A (en) 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2037153A1 (fr) 1990-03-09 1991-09-10 Leo Alig Derives de l'acide acetique
US5612311A (en) 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5721210A (en) 1990-07-09 1998-02-24 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5229366A (en) 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
AU646966B2 (en) 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
CA2078817A1 (fr) 1991-10-18 1993-04-19 Beat A. Imhof Anticorps anti-.alpha.6-integrine
US5663166A (en) 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
JPH07103148B2 (ja) 1991-12-16 1995-11-08 株式会社ディ・ディ・エス研究所 アントラサイクリン−マクロライド複合体
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5225531A (en) 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val
HUT64977A (en) 1992-07-30 1994-03-28 Yeda Res & Dev Synthetical peptone derivatives of vitronectine and pharmaceutical preparaties containing them
AU5292193A (en) * 1992-10-02 1994-04-26 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents
JPH06116289A (ja) 1992-10-09 1994-04-26 Fuji Photo Film Co Ltd 細胞接着性ペプチド配列複合体とその用途
AU679474B2 (en) * 1992-11-25 1997-07-03 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
TW301607B (fr) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE4310632A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Lineare Adhäsionsinhibitoren
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
DE4336758A1 (de) 1993-10-28 1995-05-04 Merck Patent Gmbh Lineare Adhäsionsinhibitoren
SI0656348T1 (en) 1993-12-03 2000-08-31 F. Hoffmann-La Roche Ag Aceric acid derivatives as medicaments
JP3750144B2 (ja) 1994-01-14 2006-03-01 大正製薬株式会社 ３−アリールチアゾリン誘導体
JP3235319B2 (ja) 1994-01-14 2001-12-04 大正製薬株式会社 チアゾリン誘導体
DE4405378A1 (de) 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JPH07285992A (ja) 1994-02-25 1995-10-31 Snow Brand Milk Prod Co Ltd 新規ペプチド
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE4415310A1 (de) 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
US5990112A (en) * 1996-06-18 1999-11-23 Affymax Technologies N.V. Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US5464855A (en) 1994-08-09 1995-11-07 Warner-Lambert Company Thiophene-2-carboxamidotetrazoles and pharmaceutical use thereof
US5639726A (en) 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
DK0710657T3 (da) 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
DE4439846A1 (de) 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
JPH08183788A (ja) 1994-12-28 1996-07-16 Sumitomo Pharmaceut Co Ltd １−オキサ−６−アザスピロ〔２．５〕オクタン誘導体
JPH08183752A (ja) 1994-12-28 1996-07-16 Sumitomo Pharmaceut Co Ltd シクロヘキサン誘導体
DE19504954A1 (de) 1995-02-15 1996-08-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6013651A (en) 1995-08-30 2000-01-11 G. D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof
US6100423A (en) 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
ES2161373T3 (es) 1995-08-30 2001-12-01 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
DE19534016A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Biotinderivate
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EP0765660A3 (fr) 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules contenant des acides 2-pipérazinone-1-yl-acétiques
DE19539091A1 (de) 1995-10-20 1997-04-24 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
ATE230275T1 (de) 1995-10-25 2003-01-15 Senju Pharma Co Angiogense-inhibitor
HUP9902092A3 (en) * 1995-12-08 2000-12-28 Agouron Pharmaceuticals Inc La Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
DE19626701A1 (de) 1996-07-03 1998-01-08 Hoechst Ag Neue Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
ES2171768T3 (es) 1996-03-20 2002-09-16 Hoechst Ag Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
EP0889876B1 (fr) 1996-03-29 2001-07-25 G.D. SEARLE & CO. Derives meta-substitues du sulphonamide de phenylene
DK0894084T3 (da) 1996-03-29 2002-10-14 Searle & Co Kanelsyrederivater og deres anvendelse som integrinantagonister
ES2158537T3 (es) 1996-03-29 2001-09-01 Searle & Co Derivados de acidos ciclopropilalcanoicos.
EP0889877B1 (fr) 1996-03-29 2001-08-29 G.D. Searle & Co. DERIVES DE PHENYLENE META-SUBSTITUES, UTILISES COMME ANTAGONISTES OU INHIBITEURS DE L'INTEGRINE ALPHAvBETA3
CA2250698A1 (fr) 1996-03-29 1997-10-09 G.D. Searle & Co. Derives d'acide phenylpropanoique para-substitues, utilises comme antagonistes de l'integrine
DE19613933A1 (de) 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
AU2438297A (en) * 1996-05-09 1997-11-26 Alcon Laboratories, Inc. Combinations of angiostatic compounds
DE19654483A1 (de) 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate
WO1998002410A1 (fr) 1996-07-12 1998-01-22 G.D. Searle & Co. Synthese asymetrique de beta-aminoacides chiraux
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
CN100558356C (zh) * 1996-10-15 2009-11-11 G.D.瑟尔公司 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
CN1247470A (zh) * 1996-11-19 2000-03-15 G·D·瑟尔公司 使用环加氧酶－2抑制剂作为抗血管发生剂的方法
EP0846702B1 (fr) 1996-12-09 2009-03-11 MERCK PATENT GmbH Récepteur d'adhésion alphaV beta3 récombinante soluble
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
AU729869B2 (en) * 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
AU1110799A (en) * 1997-10-29 1999-05-17 Warner-Lambert Company Method of inhibiting metastases of cancer cells
RU2250105C2 (ru) * 1997-11-14 2005-04-20 Дж.Д.Сёрл ЛЛС Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз
SI1040111T1 (en) * 1997-12-17 2005-10-31 Merck & Co., Inc. Integrin receptor antagonists
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
EP0928793B1 (fr) 1998-01-02 2002-05-15 F. Hoffmann-La Roche Ag Dérivés de thiazole
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
CZ20003672A3 (cs) * 1998-04-10 2001-08-15 G. D. Searle & Co. Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu
EP1100506A4 (fr) * 1998-07-29 2002-06-26 Merck & Co Inc Antagonistes des recepteurs de l'integrine
US6277878B1 (en) * 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents

Also Published As

Publication number Publication date
WO2000038786A3 (fr) 2001-03-08
JP2002533406A (ja) 2002-10-08
BR9916536A (pt) 2002-01-02
AU2209800A (en) 2000-07-31
AU2713600A (en) 2000-07-31
CA2356462A1 (fr) 2000-07-06
BR9916518A (pt) 2002-01-29
AU2210400A (en) 2000-07-31
CA2356929A1 (fr) 2000-07-06
WO2000037107A2 (fr) 2000-06-29
CA2356426A1 (fr) 2000-06-29
EP1140192B1 (fr) 2006-04-05
EP1140194A2 (fr) 2001-10-10
WO2000038715A2 (fr) 2000-07-06
JP2002533407A (ja) 2002-10-08
JP2002533416A (ja) 2002-10-08
CZ20012320A3 (cs) 2002-10-16
MXPA01006499A (es) 2002-04-08
HUP0104747A2 (hu) 2002-04-29
JP2002533405A (ja) 2002-10-08
WO2000038717A2 (fr) 2000-07-06
EP1140193A2 (fr) 2001-10-10
NO20013156L (no) 2001-08-23
EP1140182A2 (fr) 2001-10-10
NO20013155D0 (no) 2001-06-22
EA006294B1 (ru) 2005-10-27
JP2002533422A (ja) 2002-10-08
WO2000038715A3 (fr) 2001-01-04
WO2000037107A3 (fr) 2001-02-01
AU2593600A (en) 2000-07-12
NO20013156D0 (no) 2001-06-22
PL350291A1 (en) 2002-12-02
CA2356402A1 (fr) 2000-07-06
PL349216A1 (en) 2002-07-01
CA2356748A1 (fr) 2000-07-06
AU2713500A (en) 2000-07-31
CN1346282A (zh) 2002-04-24
EA200100572A1 (ru) 2002-02-28
ATE322290T1 (de) 2006-04-15
AU2380500A (en) 2000-07-31
EA200100573A1 (ru) 2002-02-28
JP2002533404A (ja) 2002-10-08
ZA200105120B (en) 2002-01-07
WO2000038730A2 (fr) 2000-07-06
KR20010109275A (ko) 2001-12-08
WO2000038719A1 (fr) 2000-07-06
HUP0104747A3 (en) 2002-12-28
EP1140179A2 (fr) 2001-10-10
IL143901A0 (en) 2002-04-21
JP2002533387A (ja) 2002-10-08
IL143870A0 (en) 2002-04-21
HUP0104814A2 (hu) 2002-04-29
WO2000038717A3 (fr) 2001-02-01
CA2356302A1 (fr) 2000-07-06
EP1140177A2 (fr) 2001-10-10
TR200102499T2 (tr) 2001-12-21
HUP0104814A3 (en) 2003-03-28
WO2000038665A2 (fr) 2000-07-06
CA2356606A1 (fr) 2000-07-06
CN1398189A (zh) 2003-02-19
WO2000038730A3 (fr) 2000-11-02
EP1140192A2 (fr) 2001-10-10
ZA200105055B (en) 2002-09-20
EP1140178A2 (fr) 2001-10-10
AU783992B2 (en) 2006-01-12
CN1371286A (zh) 2002-09-25
KR20010110310A (ko) 2001-12-12
AU2207000A (en) 2000-07-31
US6689787B1 (en) 2004-02-10
CZ20012321A3 (cs) 2002-10-16
WO2000038665A3 (fr) 2000-11-16
DE69930764D1 (de) 2006-05-18
WO2000038718A3 (fr) 2000-11-09
JP2002532563A (ja) 2002-10-02
AU2592600A (en) 2000-07-31
EP1140183A1 (fr) 2001-10-10
WO2000038718A2 (fr) 2000-07-06
CA2356459A1 (fr) 2000-07-06
WO2000038786A2 (fr) 2000-07-06

Similar Documents

Publication Publication Date Title
NO20013155D0 (no) Fremgangsmåte ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi
EA200100571A1 (ru) Комбинированный способ лечебного воздействия, включающий применение лучевой терапии и ингибитора циклооксигеназы-2(cox-2) для лечения неоплазии
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
CY1107174T1 (el) Συνδυασμοι εζετιμιβε με ασπιρινη για θεραπεια αγγειακων καταστασεων
DK0858330T3 (da) Præparater indeholdende derivater af hydroperoxyeicosatetraensyre og fremgangsmåder til anvendelse ved behandling af sygdom
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
NO972426L (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
TR200201724T2 (tr) Antihipertansiyon ve buna bağlı belirtileri tedavi etmek için method ve formüller
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
AT3848U3 (de) Verfahren zur unbaren abwicklung der mehrwertsteuer zwischen unternehmern und finanzverwaltung
UA36537A (uk) Спосіб утворення аутопластичного ілеоколоанастомозу при правосторонній геміколектомії

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application